PCR158 Patient Reported Outcomes (PRO) From Ongoing Phase 2 Registrational Trial of Repotrectinib in Patients With ROS1-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (TRIDENT-1)
| Autor: | Shim, A, Trone, D, Reynolds, M, Odom, D, Sherif, B, Stopatschinskaja, S |
|---|---|
| Zdroj: | In Value in Health December 2022 25(12) Supplement:S421-S421 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect